can mochi still sell tirzepatide Health Switching to Tirzepatide with Mochi

2 And those were Phase 2 numbers Phase 3 results came in even higher

The Medvi case is likely to accelerate FDA scrutiny of asynchronous prescribing as a dispensing mechanism, particularly where it intersects with compounded product supply chains that lack sterility assurance documentation or formal process validation records

MedPAC supported paying for skin substitute products as an add-on service rather than as a standalone service, noting that paying for these products as a standalone service would require CMS to assign 0.01 MP RVUs to the payment for each unit of the skin substitute the clinician applies

For diabetes use, the prescription typically suffices